Which antibiotics increase risk of sudden death in your patient on haemodialysis? Probably something you should know. Check out our rapid-fire summary tweetorial at the link!
This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
Which antibiotics increase risk of sudden death in your patient on haemodialysis? Probably something you should know. Check out our rapid-fire summary tweetorial at the link!
⚖️As doctors we guide our practice by the principle: primum, non nocere
— Nephrology Jrnl Club (@NephJC) July 22, 2022
⁉️ Premise: pt on hemodialysis develops pneumonia. What antibiotic would you use?
Welcome to #TenTweetNephJC
✳️ 10 tweets #NephJC catch-up ✳️ pic.twitter.com/PHeR0c7EkV